Literature DB >> 15734416

Comparison between clinical and pathologic staging in 2,994 cases of lung cancer.

Angel López-Encuentra1, Ricardo García-Luján, Juan José Rivas, Jesús Rodríguez-Rodríguez, Juan Torres-Lanza, Gonzalo Varela-Simo.   

Abstract

BACKGROUND: The accuracy of clinical staging in lung cancer may be evaluated by comparing it against the gold standard of pathologic staging. The objective of this paper is to compare these two staging methods in a series of 2,994 lung cancer cases operated on consecutively in Spain between 1993 and 1997.
METHODS: The raw frequency of agreement was used to compare clinical against pathologic staging and to assess the agreement. Kappa's index was used to determine the random effect of agreement.
RESULTS: Ninety-three percent of the entire population were men, with a mean age of 64 years (median, 66; SD, 9.6). The majority of cases were classified as squamous tumors (1,774; 59%), with complete resection (2,410; 80%), and with lobectomy or bilobectomy (1,490; 55%). The most frequently found pathologic stage was pIB (997; 37%), followed by pIIIA (524; 19%). Considering the 2,377 cases with clinical and pathologic staging data, a classification coincidence was observed in 1,108 cases (47%; Kappa's index 0.248 for stages IA through IIIB). Considering the pathologic staging as the gold standard, the agreement was 75% for stages IA-IB (Kappa's index 0.56). In general, downstaging is more frequent than upstaging.
CONCLUSIONS: This recent series of lung cancer showed the low diagnostic accuracy of the clinical staging as compared with the pathologic staging. Diagnostic accuracy was found to be much higher in the initial IA-IB stages, as illustrated by Kappa's index.

Entities:  

Mesh:

Year:  2005        PMID: 15734416     DOI: 10.1016/j.athoracsur.2004.06.004

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Pathologic Upstaging in Patients Undergoing Resection for Stage I Non-Small Cell Lung Cancer: Are There Modifiable Predictors?

Authors:  Matthew J Bott; Aalok P Patel; Traves D Crabtree; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-08-13       Impact factor: 4.330

2.  The 7th lung cancer TNM classification and staging system: Review of the changes and implications.

Authors:  Saeed Mirsadraee; Dilip Oswal; Yalda Alizadeh; Andrea Caulo; Edwin van Beek
Journal:  World J Radiol       Date:  2012-04-28

3.  Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis.

Authors:  Rodney J Landreneau; Daniel P Normolle; Neil A Christie; Omar Awais; Joseph J Wizorek; Ghulam Abbas; Arjun Pennathur; Manisha Shende; Benny Weksler; James D Luketich; Matthew J Schuchert
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

4.  Pathological upstaging and treatment strategy of clinical stage I small cell lung cancer following surgery.

Authors:  Hisashi Saji; Tomoyuki Miyazawa; Hideki Marushima; Haruhiko Nakamura
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Differential expression of VASP in normal lung tissue and lung adenocarcinomas.

Authors:  L Dertsiz; G Ozbilim; Y Kayisli; G A Gokhan; A Demircan; U A Kayisli
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

6.  Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients.

Authors:  Alexander Lin; Charles Wood; Christine Hill-Kayser; Rosemarie Mick; Larry Kaiser; James Metz
Journal:  Exp Ther Med       Date:  2010-09-29       Impact factor: 2.447

Review 7.  Is segmentectomy the future?

Authors:  Rodney J Landreneau; Matthew J Schuchert
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

8.  Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?

Authors:  Matthew J Bott; Aalok P Patel; Vivek Verma; Traves D Crabtree; Daniel Morgensztern; Clifford G Robinson; Graham A Colditz; Saiama Waqar; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  J Thorac Cardiovasc Surg       Date:  2016-03-12       Impact factor: 5.209

9.  Magnetic resonance imaging of the chest in the evaluation of cancer patients: state of the art.

Authors:  Marcos Duarte Guimaraes; Bruno Hochhegger; Marcel Koenigkam Santos; Pablo Rydz Pinheiro Santana; Arthur Soares Sousa; Luciana Soares Souza; Edson Marchiori
Journal:  Radiol Bras       Date:  2015 Jan-Feb

10.  A pilot study of 4'-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer.

Authors:  Ryogo Minamimoto; Jun Toyohara; Hideyuki Ito; Ayako Seike; Yoko Miyata; Miyako Morooka; Momoko Okasaki; Kazuhiko Nakajima; Kimiteru Ito; Kiichi Ishiwata; Kazuo Kubota
Journal:  EJNMMI Res       Date:  2014-03-05       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.